Paper62582
Labetalol in long-term treatment of hypertension.
Prichard BN and 1 other. Br J Clin Pharmacol, 1976. Cited by 92 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Labetalol in long-term treatment of hypertension. Papers, record 62582. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/62582
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ethanolamines | Major topic |
| Hypertension | Major topic |
| Labetalol | Major topic |
| Adrenergic Agents | |
| Adrenergic beta-Antagonists | |
| Adult | |
| Aged | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Drug Evaluation | |
| Female | |
| Humans | |
| Male | |
| Methyldopa | |
| Middle Aged | |
| Posture |
Source PubMed
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 92 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,374,093 | Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. | Klin Wochenschr | 1980 | https://conductscience.org/library/papers/7374093 | PubMed |
| 7,371,699 | Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients. | Eur J Clin Pharmacol | 1980 | https://conductscience.org/library/papers/7371699 | PubMed |
| 7,093,102 | Labetalol steady-state pharmacokinetics in hypertensive patients. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7093102 | PubMed |
| 7,093,092 | Effects of combined alpha- and beta-blockade by labetalol in patients with coronary artery disease. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7093092 | PubMed |
| 7,075,640 | Comparison of labetalol and clonidine in hypertension. | Eur J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7075640 | PubMed |
| 7,042,373 | Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients. | Eur J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7042373 | PubMed |
| 6,419,809 | "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. | Br Med J (Clin Res Ed) | 1984 | https://conductscience.org/library/papers/6419809 | PubMed |
| 6,310,204 | Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension. | Klin Wochenschr | 1983 | https://conductscience.org/library/papers/6310204 | PubMed |
| 6,151,891 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. | Drugs | 1984 | https://conductscience.org/library/papers/6151891 | PubMed |
| 6,124,264 | Labetalol in essential hypertension. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6124264 | PubMed |
| 3,908,121 | Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. | Eur J Clin Pharmacol | 1985 | https://conductscience.org/library/papers/3908121 | PubMed |
| 3,899,671 | A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension. | Eur J Clin Pharmacol | 1985 | https://conductscience.org/library/papers/3899671 | PubMed |
| 3,881,105 | Effects of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo. | Br Heart J | 1985 | https://conductscience.org/library/papers/3881105 | PubMed |
| 3,530,297 | The management of hypertension. | Br J Clin Pharmacol | 1986 | https://conductscience.org/library/papers/3530297 | PubMed |
| 2,908,732 | Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia. | Cardiovasc Drugs Ther | 1988 | https://conductscience.org/library/papers/2908732 | PubMed |
| 1,350,483 | Clinical experience with dual-acting drugs in hypertension. | Clin Investig | 1992 | https://conductscience.org/library/papers/1350483 | PubMed |
| 760,749 | Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension. | Br J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/760749 | PubMed |
| 760,748 | Rate of onset of hypotensive effect of oral labetalol. | Br J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/760748 | PubMed |
| 526,408 | Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. | Br J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/526408 | PubMed |
| 526,398 | Long-term treatment of hypertension with labetalol. | Br J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/526398 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/62582
GET https://conductscience.org/api/papers/v1/62582/cited_by?page=2